title: A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
authors.affiliation: Division of New Drugs Development and Clinical Pharmacology, European Institute of Oncology Ripamonti 435 Milan, Italy. chiara.catania@ieo.it
authors.forename: Chiara
authors.initials: C
authors.lastname: Catania
authors.forename: G
authors.initials: G
authors.lastname: Pelosi
authors.forename: N
authors.initials: N
authors.lastname: Fazio
authors.forename: R
authors.initials: R
authors.lastname: Biffi
authors.forename: G
authors.initials: G
authors.lastname: Spitaleri
authors.forename: C
authors.initials: C
authors.lastname: Noberasco
authors.forename: M G
authors.initials: MG
authors.lastname: Zampino
authors.forename: A
authors.initials: A
authors.lastname: Maggioni
authors.forename: G
authors.initials: G
authors.lastname: Trifirò
authors.forename: F
authors.initials: F
authors.lastname: Toffalorio
authors.forename: P Della
authors.initials: PD
authors.lastname: Vigna
authors.forename: F
authors.initials: F
authors.lastname: De Braud
authors.forename: T
authors.initials: T
authors.lastname: De Pas
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004379:Duodenal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin